Celldex Therapeutics, Inc. (CLDX) Position Held by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D continued to hold its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 475,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D owned approximately 0.38% of Celldex Therapeutics worth $1,173,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of CLDX. American International Group Inc. raised its stake in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 3,880 shares during the period. TSP Capital Management Group LLC raised its stake in shares of Celldex Therapeutics by 20.0% in the first quarter. TSP Capital Management Group LLC now owns 1,063,248 shares of the biopharmaceutical company’s stock valued at $3,838,000 after buying an additional 176,850 shares during the period. Raymond James Financial Services Advisors Inc. raised its stake in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares during the period. State of Wisconsin Investment Board raised its stake in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock valued at $2,708,000 after buying an additional 505,138 shares during the period. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 1,409 shares during the period. 63.88% of the stock is owned by hedge funds and other institutional investors.

Shares of Celldex Therapeutics, Inc. (CLDX) opened at 2.33 on Friday. The stock has a 50 day moving average price of $2.44 and a 200-day moving average price of $2.97. The company’s market cap is $299.03 million. Celldex Therapeutics, Inc. has a 1-year low of $2.20 and a 1-year high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. During the same quarter last year, the firm earned ($0.32) EPS. The firm’s revenue for the quarter was up 175.5% compared to the same quarter last year. Equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.04) earnings per share for the current year.

WARNING: This news story was first reported by [[site]] and is the property of of [[site]]. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at [[permalink]].

Several brokerages have issued reports on CLDX. Jefferies Group LLC reaffirmed a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Wednesday, May 31st. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. HC Wainwright set a $10.00 price target on Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.